Literature DB >> 10525320

Impaired production of IL-12 in systemic lupus erythematosus. III: deficient IL-12 p40 gene expression and cross-regulation of IL-12, IL-10 and IFN-gamma gene expression.

T F Liu1, B M Jones, R W Wong, G Srivastava.   

Abstract

Interleukin 12 (IL-12) is a heterodimer comprising p35 and p40 subunits which are encoded and regulated separately. The authors previously demonstrated deficient IL-12 production in SLE which correlates negatively with disease activity. The present study was designed to determine whether deficiency of IL-12 and excess production of IL-10 and IL-6 in systemic lupus erythematosus (SLE) are due to aberrant regulation at the gene level. Using semiquantitative RT-PCR assay, it was shown that constitutive expression of IL-12 p35 gene is somewhat impaired in SLE compared with controls and that IL-12 p40 mRNA, which was present at low levels in controls, was undetectable in unstimulated SLE peripheral blood mononuclear cells (PBMC). Gene expression of IL-12 p35 and p40 was significantly increased in response to SAC, with significantly lower SAC-induced expression of p40 in SLE patients than controls. SAC-stimulated IL-12 p35 and p40 mRNAs were significantly augmented by interferon gamma (IFN-gamma). Exogenous IL-12 or IFN-gamma significantly inhibited IL-10 gene expression, without affecting IL-6 mRNA or other proinflammatory cytokine mRNA levels. These observations were further confirmed by studies of protein production at the single cell level using ELISPOT assay. Downregulation of IL-12 p40 expression appears to be the cause of IL12 p70 deficiency in SLE. If this defect could be repaired, normalization of IL-12 and IFN-gamma production should reduce excessive IL-10 and prevent pathology. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10525320     DOI: 10.1006/cyto.1999.0512

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  9 in total

1.  Innate lymphoid cell disturbance with increase in ILC1 in systemic lupus erythematosus.

Authors:  Chaohuan Guo; Mianjing Zhou; Siyuan Zhao; Yuefang Huang; Shuang Wang; Rong Fu; Mengyuan Li; Tengyue Zhang; Felicia Gaskin; Niansheng Yang; Shu Man Fu
Journal:  Clin Immunol       Date:  2019-03-26       Impact factor: 3.969

2.  Functional genetic polymorphisms in interleukin-12B gene in association with systemic lupus erythematosus.

Authors:  Lyuba D Miteva; Irena M Manolova; Mariana G Ivanova; Rasho K Rashkov; Rumen M Stoilov; Maya V Gulubova; Spaska A Stanilova
Journal:  Rheumatol Int       Date:  2010-07-24       Impact factor: 2.631

3.  Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies.

Authors:  L Mathsson; E Ahlin; C Sjöwall; T Skogh; J Rönnelid
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

Review 4.  Cytokines in systemic lupus erythematosus.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

5.  Overexpression of interleukin-12 and T helper 1 predominance in lupus nephritis.

Authors:  M Tucci; L Lombardi; H B Richards; F Dammacco; F Silvestris
Journal:  Clin Exp Immunol       Date:  2008-09-15       Impact factor: 4.330

6.  Lupus patients with pulmonary involvement have a pro-inflammatory cytokines profile.

Authors:  Sana Al-Mutairi; Adel Al-Awadhi; Raj Raghupathy; Hanaa Al-Khawari; Prio Sada; Adeebah Al-Herz; Parvez Rawoot
Journal:  Rheumatol Int       Date:  2006-11-14       Impact factor: 3.580

7.  New-onset autoantibody-mediated nephritis during ustekinumab therapy for psoriasis in patients with and without prior systemic lupus erythematosus.

Authors:  Ayida Al Khalili; Leah Scott; Jan P Dutz
Journal:  JAAD Case Rep       Date:  2019-08-02

8.  Medicinal Plant Extracts and Natural Compounds for the Treatment of Cutaneous Lupus Erythematosus: A Systematic Review.

Authors:  Janet E Lubov; Aisha S Jamison; Becky Baltich Nelson; Alice A Amudzi; Kelly N Haas; Jillian M Richmond
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.988

Review 9.  Microarray profiling of lymphocytes in internal diseases with an altered immune response: potential and methodology.

Authors:  Anatoliy Gladkevich; S Adriaan Nelemans; Henk F Kauffman; Jakob Korf
Journal:  Mediators Inflamm       Date:  2005-12-14       Impact factor: 4.711

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.